News
AGRX
0.374
-0.98%
-0.004
Weekly Report: what happened at AGRX last week (0513-0517)?
Weekly Report · 1d ago
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024
Agile Therapeutics reported earnings per share of -63 cents for the first quarter of 2024. The company reported revenue of $ million. This was better than the analyst estimate for revenue of $ million. Agile TherAPEutics just reported results.
Investorplace · 6d ago
Agile Therapeutics, Inc. Quarterly Report on Form 10-Q for the Quarter Ended March 31, 2024
Press release · 6d ago
Agile Therapeutics Non-GAAP EPS of -$0.63, revenue of $5.7M
Seeking Alpha · 6d ago
*Agile Therapeutics 1Q EPS 28c >AGRX
Dow Jones · 6d ago
Agile Therapeutics: Q1 Earnings Snapshot
Barchart · 6d ago
Weekly Report: what happened at AGRX last week (0506-0510)?
Weekly Report · 05/13 09:56
Weekly Report: what happened at AGRX last week (0429-0503)?
Weekly Report · 05/06 09:59
Weekly Report: what happened at AGRX last week (0422-0426)?
Weekly Report · 04/29 10:01
Weekly Report: what happened at AGRX last week (0415-0419)?
Weekly Report · 04/22 09:58
Weekly Report: what happened at AGRX last week (0408-0412)?
Weekly Report · 04/15 09:54
Agile Therapeutics Releases Updated Investor Presentation
TipRanks · 04/09 12:43
Weekly Report: what happened at AGRX last week (0401-0405)?
Weekly Report · 04/08 09:55
Weekly Report: what happened at AGRX last week (0325-0329)?
Weekly Report · 04/01 09:55
Agile Therapeutics’ Balancing Act: Funding Challenges Threaten R&D and Twirla Rollout
TipRanks · 03/30 06:01
AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023
Agile Therapeutics reported results for the fourth quarter of 2023. The company reported earnings per share of -$1.46 and revenue of $3.62 million. This was 11.18% below the analyst estimate for revenue of - $4.07 million.
Investorplace · 03/30 00:52
Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate
Agile Therapeutics reported quarterly losses of $1.46 per share. The company missed the analyst consensus estimate of $0.92 per share by 58.7%. The company also reported quarterly sales of $3.62 million which missed the estimate by 11.18 percent.
Benzinga · 03/28 12:17
Agile Therapeutics reports Q4 results
Seeking Alpha · 03/28 12:13
Agile Therapeutics: Q4 Earnings Snapshot
Agile Therapeutics Inc. Reports a loss of $4.5 million in its fourth quarter. The developer of prescription contraceptive products for women posted revenue of $3.6 million in the period. For the year, the company's loss narrowed to $6.71 per share.
Barchart · 03/28 07:22
Agile Therapeutics Q4 2023 Earnings Preview
Seeking Alpha · 03/27 16:31
More
Webull provides a variety of real-time AGRX stock news. You can receive the latest news about Agile Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGRX
Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The Company commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.